| 1 |
35022929 | Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. | 2022 Jun |
2 |
| 2 |
35602875 | Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma. | 2022 May-Jun |
1 |
| 3 |
33295758 | Enhanced Bioactivity of a Human GHR Antagonist Generated by Solid-Phase Site-Specific PEGylation. | 2021 Feb 8 |
1 |
| 4 |
33553983 | Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly. | 2021 Mar 1 |
2 |
| 5 |
33960325 | Improved AcroQoL scores in acromegaly after sagittal split ramus osteotomy with Le Fort I osteotomy. | 2021 Apr 1 |
1 |
| 6 |
34342594 | More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. | 2021 Aug 27 |
2 |
| 7 |
31917681 | All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. | 2020 Mar |
1 |
| 8 |
30772778 | First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. | 2019 Apr |
4 |
| 9 |
31365626 | Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia). | 2019 Jul 29 |
1 |
| 10 |
29080965 | How to improve effectiveness of pegvisomant treatment in acromegalic patients. | 2018 May |
4 |
| 11 |
29155991 | Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). | 2018 Feb 1 |
1 |
| 12 |
29672904 | Growth hormone-Insulin-like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune-Albright Syndrome. | 2018 Jul |
1 |
| 13 |
29953972 | Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant. | 2018 |
3 |
| 14 |
27455094 | Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. | 2017 |
4 |
| 15 |
27513761 | The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis. | 2017 |
2 |
| 16 |
27631335 | Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. | 2017 Feb |
2 |
| 17 |
27932529 | Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. | 2017 Feb |
3 |
| 18 |
28100630 | A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. | 2017 Apr |
9 |
| 19 |
28176221 | Pegvisomant in acromegaly: an update. | 2017 Jun |
1 |
| 20 |
28902627 | Serum α-klotho levels are not informative for the evaluation of growth hormone secretion in short children. | 2017 Oct 26 |
1 |
| 21 |
29278515 | Pegvisomant-primed growth hormone (GH) stimulation test is useful in identifying true GH deficient children. | 2017 Jul |
1 |
| 22 |
30058878 | Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. | 2017 Jan |
1 |
| 23 |
26553421 | Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. | 2016 Apr |
1 |
| 24 |
26661938 | Combined treatment of somatostatin analogues with pegvisomant in acromegaly. | 2016 May |
1 |
| 25 |
26662620 | Long-term treatment with pegvisomant for acromegaly: a 10-year experience. | 2016 Apr |
2 |
| 26 |
26796763 | Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. | 2016 Apr 25 |
3 |
| 27 |
26903550 | What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy? | 2016 May |
7 |
| 28 |
27241667 | Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. | 2016 Aug 28 |
1 |
| 29 |
27267119 | In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. | 2016 Jul |
4 |
| 30 |
27287035 | Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. | 2016 Oct |
1 |
| 31 |
27401863 | Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY. | 2016 Oct |
3 |
| 32 |
27448708 | Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. | 2016 Oct |
1 |
| 33 |
25712922 | X-linked acrogigantism syndrome: clinical profile and therapeutic responses. | 2015 Jun |
1 |
| 34 |
25813261 | [Akromegaly and pharmacotherapy]. | 2015 Feb |
1 |
| 35 |
25962899 | A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression. | 2015 May 12 |
4 |
| 36 |
26224528 | Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. | 2015 Dec |
1 |
| 37 |
26243033 | Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. | 2015 Nov |
5 |
| 38 |
26429918 | Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. | 2015 Nov |
3 |
| 39 |
26596374 | Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. | 2015 Dec |
3 |
| 40 |
23650996 | Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. | 2014 Jan |
3 |
| 41 |
24035867 | Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. | 2014 Apr 5 |
1 |
| 42 |
24423298 | Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes. | 2014 Feb |
1 |
| 43 |
24517150 | Acromegaly and McCune-Albright syndrome. | 2014 Jun |
1 |
| 44 |
24913198 | Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. | 2014 Jul |
5 |
| 45 |
22396133 | Pegvisomant and cabergoline combination therapy in acromegaly. | 2013 Mar |
1 |
| 46 |
23038625 | Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. | 2013 Jan |
3 |
| 47 |
23103101 | [Optimization of the medical treatment for acromegaly]. | 2013 Apr 20 |
1 |
| 48 |
23337021 | Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient. | 2013 Feb |
1 |
| 49 |
23785020 | Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist. | 2013 Jul |
1 |
| 50 |
30349613 | Extra-hepatic Acromegaly. | 2013 Mar |
5 |